Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Rush University Medical Center GlaxoSmithKline |
---|---|
Information provided by: | Rush University Medical Center |
ClinicalTrials.gov Identifier: | NCT00891436 |
Rationale and objectives:
Fluticasone furoate nasal spray (Veramyst) has been shown to improve ocular symptoms when used for the treatment of seasonal allergic rhinitis during the ragweed pollen season. Although this is the only published report of an intranasal corticosteroid shown to effectively treat ocular symptoms, the mechanism has not been delineated. Furthermore, the tears of patients with allergic conjunctivitis are known to have increased concentrations of cytokines and allergic mediators.
The objective of this study is to determine if the positive effects of Veramyst nasal spray on ocular symptoms is via the inhibition of allergic mediators in the eyes. The investigators will conduct a double blind placebo controlled trial to determine if Veramyst nasal spray decreases the amount of allergic mediators in the tears of subjects randomized to Veramyst nasal spray versus placebo. The investigators will also compare the subjects' symptoms to the amount of allergic mediators detected in their tears.
Condition | Intervention | Phase |
---|---|---|
Allergic Conjunctivitis to Tree Pollen or Grass Pollen |
Drug: Fluticasone furoate nasal spray Drug: Placebo nasal spray |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment |
Official Title: | Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy |
Estimated Enrollment: | 20 |
Study Start Date: | April 2009 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Placebo nasal spray: Placebo Comparator |
Drug: Placebo nasal spray
2 sprays each nostril every morning for 2 weeks
|
Fluticasone furoate nasal spray: Active Comparator |
Drug: Fluticasone furoate nasal spray
2 sprays each nostril every morning for 2 weeks
|
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Illinois | |
Rush University Medical Center | |
Chicago, Illinois, United States, 60612 |
Principal Investigator: | J. Moy, MD | Rush University Medical Center |
Responsible Party: | Rush University Medical Center ( James N. Moy, MD ) |
Study ID Numbers: | RUMCgsk 113002 |
Study First Received: | April 30, 2009 |
Last Updated: | April 30, 2009 |
ClinicalTrials.gov Identifier: | NCT00891436 History of Changes |
Health Authority: | United States: Institutional Review Board |
Anti-Inflammatory Agents Lacerations Conjunctivitis, Allergic Eye Diseases Anti-Asthmatic Agents Conjunctivitis Anti-Allergic Agents |
Conjunctival Diseases Hypersensitivity Rhinitis, Allergic, Seasonal Hypersensitivity, Immediate Fluticasone Peripheral Nervous System Agents Bronchodilator Agents |
Anti-Inflammatory Agents Respiratory System Agents Conjunctivitis, Allergic Immune System Diseases Eye Diseases Physiological Effects of Drugs Anti-Asthmatic Agents Anti-Allergic Agents Conjunctivitis Conjunctival Diseases |
Pharmacologic Actions Hypersensitivity Autonomic Agents Therapeutic Uses Hypersensitivity, Immediate Fluticasone Peripheral Nervous System Agents Dermatologic Agents Bronchodilator Agents |